On Monday shares of Myriad Genetics (NASDAQ: MYGN) declined on concerns about medical reimbursement. In the view of Leerink Swann ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE